The FDA approved Moderna’s COVID-19 vaccine, Spikevax, in children between the ages of 6 months and 11 years who are at increased risk for COVID-19 disease.
Spikevax is already indicated for people between 12 and 64 years of age who are at increased risk, and for those who are 65 and older. Previously, Moderna’s COVID-19 vaccine mRNA-1273 was available for children under an emergency use authorization.